Use of Pancreatic Enzymes in Short Bowel Syndrome

Summary

Patients with short bowel syndrome have a high mortality rate that is mainly attributed to complications from central lines and long-term intravenous (IV) nutrition. There are few medical therapies to date that improve gut absorption in patients with short bowel syndrome. The primary objective of this study is to evaluate if absorption from the GI tract improves in subjects with short bowel syndrome following therapy with pancreatic enzymes.

Timeline

Start

2017-03-24

Primary completion

2019-02-01

Completion

2019-02-01

Outcome

Missed primary endpoint

paper There was no statistically significant mean change in CFA and CNA before and after pancreatic enzyme medication therapy. PMID 35622082 ↗

Publications

• Sainath NN, Bales C, Brownell JN, Pickett-Blakely O, Sattar A, Stallings VA. Impact of Pancreatic Enzymes on Enteral Fat and Nitrogen Absorption in Short Bowel Syndrome. J Pediatr Gastroenterol Nutr. 2022 Jul 1;75(1):36-41. doi: 10.1097/MPG.0000000000003465. Epub 2022 May 27.

Drugs

Indications